Farzaneh Afzali

Farzaneh Afzali

Auto-generated profile, based on publicly available information

Farzaneh Afzali

National Institute of Genetic Engineering and Biotechnology (NIGEB)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2019 in Interdisciplinary Sciences: Computational Life Sciences
Verified
Journal Article
Closed access
PDF file
FAFarzaneh Afzali
Farzaneh Afzali
MSMahdieh Salimi
Mahdieh Salimi

26 August 2019 in International Journal of Peptide Research and Therapeutics
Verified
Journal Article
Closed access
PDF file
Parisa GhahremanifardParisa Ghahremanifard
Parisa Ghahremanifard
FAFarzaneh Afzali
Farzaneh Afzali
ARAmin Rostami
Amin Rostami
ZNZahra Nayeri
Zahra Nayeri
BBBijan Bambai
Bijan Bambai
ZMZarrin Minuchehr
Zarrin Minuchehr

16 July 2020 in Current Proteomics
Verified
Journal Article
Closed access
PDF file
FAFarzaneh Afzali
Farzaneh Afzali
Parisa GhahremanifardParisa Ghahremanifard
Parisa Ghahremanifard
MRMohammad Mehdi Ranjbar
Mohammad Mehdi Ranjbar
MSMahdieh Salimi
Mahdieh Salimi
Background: The tolerogenic homeostasis in Breast Cancer (BC) can be surpassed by rationally designed immune-encouraging constructs against tumor-specific antigens through immunoinformatics approach. Objective: Availability of high throughput data providing the underlying concept of diseases and awarded computational simulations, lead to screening the potential medications and strategies in less time and cost. Despite the extensive effects of Placenta Specific 1 (PLAC1) in BC progression, immune tolerance, invasion, cell cycle regulation, and being a tumor-specific antigen the fundamental mechanisms and regulatory factors were not fully explored. It is also worth to design an immune response inducing construct to surpass the hurdles of traditional anti-cancer treatments. Methods and Result: The study was initiated by predicting and modelling the PLAC1 secondary and tertiary structures and then engineering the fusion pattern of PLAC1 derived immunodominant predicted CD8+ and B-cell epitopes to form a multi-epitope immunogenic construct. The construct was analyzed considering the physiochemical characterization, safety, antigenicity, post-translational modification, solubility, and intrinsically disordered regions. After modelling its tertiary structure, proteinprotein docking simulation was carried out to ensure the attachment of construct with Toll-Like Receptor 4 (TLR4) as an immune receptor. To guarantee the highest expression of the designed construct in E. coli k12 as an expressional host, the codon optimization and in-silico cloning were performed. The PLAC1 related miRNAs in BC were excavated and validated through TCGA BC miRNA-sequencing and databases; the common pathways then were introduced as other probable mechanisms of PLAC1 activity. Conclusion: Regarding the obtained in-silico results, the designed anti-PLAC1 multi-epitope construct can probably trigger humoral and cellular immune responses and inflammatory cascades, therefore may have the potential of halting BC progression and invasion engaging predicted pathways.

27 February 2019 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
FAF. Afzali
F. Afzali
PAP. Akbari
P. Akbari
HNH. Naderi-Manesh
H. Naderi-Manesh
MGMossa Gardaneh
Mossa Gardaneh

9 March 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
Parisa GhahremanifardParisa Ghahremanifard
Parisa Ghahremanifard
FAFarzaneh Afzali
Farzaneh Afzali
ARAmin Rostami
Amin Rostami
ZNZahra Nayeri
Zahra Nayeri
BBBijan Bambai
Bijan Bambai
ZMZarrin Minuchehr
Zarrin Minuchehr
Hepatocellular carcinoma (HCC) is one of the leading cancer-related deaths worldwide. Recently, studies for HCC treatment are focused on cancer immunotherapy, particularly cancer vaccines, to complete and assist other therapies. TPX2 is a microtubule-associated protein necessary for cell division; therefore, alteration in its expression, especially up regulation, is associated with several human carcinomas such as HCC. In this study, immunoinformatics tools were used to design a rational multi-epitope T vaccine against TPX2 in HCC. Cytotoxic T lymphocytes (CTL) and Helper T lymphocytes (HTL) epitopes were predicted and Maltose-binding protein (MBP) was added to the construct as an adjuvant. Evaluation of vaccine properties was indicated that our construct is stable and immunogenic enough to induce relevant responses besides not being allergic. After predicting the tertiary structure and energy minimization, protein-protein docking was performed to calculate the free energy of possible interactions between the vaccine and toll-like receptor 4 (TLR4) to assure that simultaneous complementary responses would be activated by our construct. Finally, Codon optimization and in-silico cloning were performed to ensure the vaccine expression efficiency in the desired host.

5 March 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
FAFarzaneh Afzali
Farzaneh Afzali
ZNZahra Nayeri
Zahra Nayeri
ZMZarrin Minuchehr
Zarrin Minuchehr
MGMossa Gardaneh
Mossa Gardaneh
Nearly 16% of people with breast cancer (BC) have Diabetes Mellitus type 2 (DM2) and are at a higher risk of death worldwide. Their common regulatory factors and functional mechanisms can be targeted applying multi-target drugs including Metformin (MTFN) and Curcumin (CURC). In this study, we used in-silico approaches to study the potential underlying mechanisms of this co-treatment strategy on BC and DM2 in order to introduce novel therapeutic targets. The total number of 48 shared differentially expressed genes (17 up-regulated and 31 down-regulated) were identified through establishing diseases’ protein-protein network and BC RNA-sequencing expression data. The integration of functional clustering and pathway analyses revealed that the most involved cellular pathways and processes are regard to cells’ proliferation, death, migration, and response to external stimulus. Afterwards, the MTFN/CURC correlation and co-treatment optimization was probed through response surface methodology (RSM) based on MCF7 cell line and confirmed by MDA-MB-231. Combination index calculation by MTT viability assay proved supportive effects on both cell lines. The superior apoptotic potential of co-treatment compared to single treatments was shown on inhibition of MCF7 proliferation and induction of cell death demonstrated by cell body co-staining and flow cytometry as well as gene expression analysis via RT-PCR. Furthermore, wound-healing scratch assay showed that this co-treatment has a slightly higher effect on migration inhibition compared to single treatments. In conclusion, our study used in-silico and in-vitro approaches and introduced a potential regulatory panel between BC and DM2. We also provided a linear model and equation that show the positive relation of drugs’ co-treatment. The proposed co-treatment strategy successfully controlled the biological processes under investigation.